With few exceptions, CA found in CAD have specificity for the erythrocyte surface carbohydrate antigen termed I (Wiener et al, 1956; Issitt, 1968; Ulvestad et al, 1999) . Specificity for the protein antigen Pr is found in rare cases (Wang et al, 1973) . Determination of the titre is used for a semiquantitative assessment of CA activity in serum. The thermal amplitude (TA), defined as the highest temperature at which the cold-reactive antibody will react with its antigen, is more important than the titre for pathogenicity (Schubothe, 1966; Rosse & Adams, 1980) . Furthermore, monoclonal CA are more pathogenic than polyclonal CA (Stone et al, 2003; Berentsen & Tjonnfjord, 2012) .
Today, CAD is considered a well-defined clinico-pathological entity (Randen et al, 2014; Berentsen, 2016; Baines & Brodsky, 2017; Jaeger, 2017) . It should be distinguished from secondary CA syndrome (CAS), a similar but still more uncommon cold haemolytic syndrome complicating a distinct underlying clinical disease . The most frequent causes of CAS are Mycoplasma pneumoniae pneumonia, Epstein-Barr virus infection, or aggressive lymphoma (Dacie, 1992a; Berentsen & Tjonnfjord, 2012) . Only CAD will be further addressed in this review.
CAD is an uncommon disease that mainly affects elderly or middle-aged people (Berentsen et al, 2006; Swiecicki et al, 2013; Barcellini et al, 2014; Mullins et al, 2017) . A descriptive, population-based study in Norway found a prevalence of 16 per million inhabitants and an incidence rate of 1 per million inhabitants per year, which is probably an underestimation (Berentsen et al, 2006) . The median age of patients with CAD at the time of the study was 76 years (range, 51-96) with a median age at onset of symptoms of 67 years (range, 30-92) .
Therapy was largely unsuccessful until the last two decades (Dacie, 1992b; Berentsen et al, 2006; Swiecicki et al, 2013) . In recent years, substantial progress has been made in the knowledge of pathogenesis and possible targets for therapeutic agents; and efficient therapies have become available. British guidelines for diagnosis and treatment of AIHA including CAD have recently been published (Hill et al, 2017a,b) . This review will describe the clinical and pathogenetic features relevant for the development of recent and future treatment options in CAD. Based on these findings and prospective trials, I will discuss the optimal current management.
Pathogenesis

CAD is a lymphoproliferative bone marrow disorder
The first monoclonal protein ever described was a CA from a patient with CAD (Christenson et al, 1957) , and the occurrence of abnormal IgM with j light chain restriction was recurrently found in subsequent studies (Harboe & Deverill, 1964) . Selective usage of the IGHV4-34 gene segment was demonstrated during the 1990s (Pascual et al, 1992) . A few years later, we were able to verify an abnormal B cell clone by flow cytometry in bone marrow aspirates from 10 of 11 patients with primary CAD, most of whom had also a demonstrable lymphoproliferative disorder (LPD) by bone marrow biopsy (Berentsen et al, 1997) . In a larger cohort of 86 patients, we confirmed serum monoclonal IgMj in more than 90%, while IgG, IgA or k light chain phenotype were rare findings (Berentsen et al, 2006) . Upon re-examining the records for other findings indicating a B cell LPD, we found that clonal CD20 + , j + lymphocytes had been detected in bone marrow aspirates from 90% of patients who had been immunophenotyped by flow cytometry. Morphological and/or immune histochemical signs of a bone marrow clonal LPD were described in 50 (76%) of 66 patients who had undergone a trephine biopsy examination (Berentsen et al, 2006) . This descriptive, combined cross-sectional and retrospective study did not include a centralized review of all biopsy samples, and we interpreted the histology findings as being heterogeneous. In 33 of 50 biopsies, the LPD was classified as lymphoplasmacytic lymphoma (LPL); eight were diagnosed as marginal zone lymphoma (MZL) and the remaining 18 as clonal lymphocytosis or small lymphocytic B cell lymphoma. A retrospective study from the USA supported the idea of heterogeneity regarding the associated low-grade LPD (Swiecicki et al, 2013) .
A more recent, comprehensive study revealed the apparent explanation for this perceived heterogeneity (Randen et al, 2014) . Bone marrow biopsy samples and aspirates from 54 patients with CAD were systematically re-examined by a group of lymphoma pathologists, using a standardized panel of morphological, immunohistochemical, flow cytometric and molecular methods. The findings were consistent with a surprisingly homogeneous bone marrow disorder, termed 'primary CA-associated LPD' and found to be distinct from LPL, MZL and other previously recognized lymphoma entities (Fig 1) . We found nodular B cell aggregates in the bone marrow biopsy specimens from 40 out of 54 patients, whereas 14 patients showed only scattered B cells. In the samples showing aggregates, median lymphoid infiltration was 10% of the intertrabecular surface (range, 5-80%). Specific features of LPL were not seen, such as paratrabecular growth, fibrosis, lymphoplasmacytoid cell morphology or an increased number of mast cells surrounding the lymphoid aggregates. Differences between CAD and LPL were also observed by immunohistochemical and flow cytometric analysis (Randen et al, 2014) . Importantly, the MYD88 L265P mutation, present in almost all cases of LPL (Treon et al, 2012) , could not be demonstrated in CA-associated LPD (Randen et al, 2014) . The absence or low frequency of this mutation in CAD has been confirmed in two subsequent studies (de Tute et al, 2015; Malecka et al, 2016) .
A British flow cytometry study also showed significant immune phenotypic differences in clonal B cells between CAD and Waldenstr€ om macroglobulinaemia/LPL (de Tute et al, 2015) . In addition to the previously demonstrated, selective IGHV4-34 heavy chain gene usage in primary CAD, a recent Norwegian study also found a highly restricted light chain gene expression (Malecka et al, 2015 (Malecka et al, , 2016 . Clonal rearrangement of the IGKV3-20 gene sequence was seen in 16 of 27 patients; seven of these displayed highly homologous CDR3 regions. In another recent study of 16 patients with well-characterized primary CAD, using flow cytometryassisted cell sorting of bone marrow, whole-exome and targeted sequencing of clonal B cells with T cells as control, recurrent mutations of KMT2D and CARD11 were detected in 11 (69%) and 5 patients (31%), respectively ). An Austrian group studied 20 patients with CAmediated AIHA with regard to evidence of a clonal LPD (Arthold et al, 2014) . Among four subjects who had no demonstrable monoclonal Ig and no signs of lymphoma by bone marrow histology, a clonal rearrangement of Ig heavy and/or light chain genes could still be found in three of them.
Taken together, these findings confirm that CAD is a clonal LPD of the bone marrow in probably all cases. This LPD should be regarded a distinct entity, well-characterized by a total of morphological, immune histochemical, flow cytometric and molecular genetic findings.
Haemolysis in CAD is entirely complement-dependent
During passage through acral parts of the body, cooling of the blood allows CA to bind to erythrocytes and cause agglutination (Ulvestad et al, 1999) . The antigen-IgM complex binds complement protein 1q (C1q) on the cell surface and initiates the classical complement pathway, as shown in Fig 2 (Ulvestad et al, 1999; Berentsen, 2014; Shi et al, 2014; Baines & Brodsky, 2017) . C1 esterase activates C2 and C4, generating C3 convertase which results in the cleavage of C3 to C3a and C3b. Upon warming to 37°C in the central circulation, the CA detach from the cells, allowing agglutinated erythrocytes to separate, while C3b remains bound. C3b-opsonized cells are prone to phagocytosis by the mononuclear phagocytic system, mainly in the liver, a process known as extravascular haemolysis (Schreiber & Frank, 1972a,b; Jaffe et al, 1976) . On the surface of the surviving erythrocytes, C3b is cleaved, leaving high numbers of C3d molecules that can be detected by the direct antiglobulin test (DAT). Furthermore, C3d has been shown to protect red blood cells from phagocytosis, which at least partly explains why most patients with this disorder do not develop life-threatening anaemia (Jaffe et al, 1976) .
The classical complement pathway-mediated, extravascular haemolysis is probably the predominant mechanism of erythrocyte destruction in stable disease (Shi et al, 2014; Berentsen et al, 2015) . At least in some patients and situations, however, complement activation is thought to proceed beyond the C3 stage, causing cleavage of C5 and thereby triggering the terminal complement cascade with formation of the membrane attack complex (MAC) and intravascular haemolysis . This notion is supported by the occurrence of haemoglobinuria in about 15% of the patients (Swiecicki et al, 2013) , the rather frequent finding of haemosiderinuria (Stone & Berentsen, 2017) , and the modest but statistically significant beneficial effect of therapy with eculizumab (R€ oth et al, 2009 , 2015 Tjonnfjord et al, 2017) .
Because of the complement consumption, most patients with CAD in steady state have low serum levels of C3 and often undetectable levels of C4, which is probably rate-limiting for the haemolysis (Ulvestad et al, 1999 (Ulvestad et al, , 2001 . During febrile infections and following major surgery or major trauma, acute phase reaction will cause enhanced production of complement proteins and the low levels are replete, and exacerbation of haemolysis may ensue.
Diagnosis and clinical features
According to the most often published diagnostic criteria, CAD is defined by chronic haemolysis, CA titre ≥64 at 4°C and typical findings by the DAT (Dacie, 1992c; Ulvestad et al, 1999; Berentsen et al, 2006; Berentsen, 2016) . The typical pattern for DAT is a positive polyspecific test and a monospecific test positive for C3d only. However, DAT can be weakly positive for IgG in addition to C3d in up to 20% of the patients (Berentsen et al, 2006; Swiecicki et al, 2013) . It should also be emphasized that not all subjects with a positive DAT for C3d have CAD, CAS or even AIHA (Barcellini et al, 2014; Lauda-Maillen et al, 2017) . Determination of the TA is time-consuming and, in most cases, not required for a reliable diagnosis, but may be useful in selected patients to rule out normally occurring low-titre CA as a cause of false positive findings. Clinical assessment, in a minority of cases supplemented by radiological examinations as needed, will rule out the differential diagnosis of CAS secondary to a clinically malignant disease (Berentsen & Tjonnfjord, 2012) . Table I summarizes the diagnostic criteria for CAD.
A peripheral blood smear should always be examined although specificity is limited. Agglutination of erythrocytes is the most typical finding, often combined with features suggesting compensatory haematopoiesis, such as anisocytosis and polychromasia (Berentsen & Tjonnfjord, 2012) . The agglutination regularly results in spuriously high mean corpuscular volume (MCV) and false reduction in red blood cell counts, making estimated haematocrit values unreliable. Rarely, agglutination of granulocytes and monocytes may also be seen, probably also due to presence of the I antigen on the leucocyte surface (Pruzanski et al, 1975) . In a few cases, this may result in spurious total or differential white blood cell counts (Glasser, 2005) .
Examinations to detect a clonal LPD are not required for diagnosis, as this may be a matter of sensitivity, but should be done because the results may be confirmatory and have therapeutic implications. Such workup includes quantification of serum Ig classes, capillary or agarose electrophoresis with immunofixation, flow cytometric immunophenotyping in bone marrow aspirate and examination of a bone marrow biopsy sample by an experienced haematopathologist. For serum electrophoresis, other Ig analyses and CA titration, it is of critical importance to keep blood specimens at 37-38°C from sampling until the serum has been removed from the clot (Dacie, 1992c; Berentsen, 2016) .
In a minority of healthy people, blood tests will detect CA that have no clinical significance (Bendix et al, 2014; Mauro et al, 2017) . A frequency of positive screening tests at 0Á3% was reported in a large cohort of patients with nonrelated disorders, but only 43% of these had demonstrable CA by titration (Jain et al, 2013) . Among 16 subjects identified with detectable CA by screening patients scheduled for cardiac surgery, six were diagnosed with CAD (Barbara et al, 2013) . Thus, incidentally detected CA occur more frequently than CAD; and patients with demonstrable CA without haemolysis or circulatory manifestations do not have CAD. The normally occurring CA are polyclonal, have a low TA and are found in low titres, usually below 64 and rarely exceeding 256 (Dacie, 1992d; Bendix et al, 2014) . In contrast, among 172 subjects with monoclonal IgM in serum and CA titre between 512 and 65 500, haemolysis was found in every case (Stone et al, 2003) . The clinical presentation in CAD often provides an important clue to the differential diagnosis. At least in cold or cool climates, 90% of the patients have cold-induced circulatory symptoms, which can range from slight acrocyanosis to disabling Raynaud phenomena (Berentsen et al, 2006) . In the same study, we calculated the median haemoglobin (Hb) level as 89 g/l and the lower tertile as 80 g/l (range, 45 g/l to normal; a few patients had fully compensated haemolysis). Although the term "cold" primarily relates to the immunological properties of the autoantibodies, characteristic seasonal variations in haemolysis have been demonstrated in individual patients (Lyckholm & Edmond, 1996) . About 70% of the patients have experienced exacerbation of anaemia during febrile infections, as explained above (Ulvestad et al, 2001 ). Approximately 50% of untreated patients have been considered transfusion dependent for shorter or longer periods (Berentsen et al, 2006) .
The prognosis for survival is good. According to the Norwegian descriptive study, median survival was 12Á5 years from diagnosis, which did not differ significantly from that of an age-matched general population. Transformation of the associated bone marrow low-grade LPD to an aggressive lymphoma is a rare event, found to occur in only 3-4% of the patients during 12Á5 years' observation (Berentsen et al, 2006) . A risk of thromboembolic complications has been well documented for AIHA in general but has been more difficult to show for CAD in particular (Barcellini et al, 2014) . Some studies of (probably) selected patients did report an increased frequency of such events in CAD (R€ oth et al, 2015; Mullins et al, 2017) . A recent, large, registry-based study of individuals with the term CAD repeatedly mentioned in their medical records found a relative frequency of between 1Á5 and 2Á0 as compared to age-matched controls (Broome et al, 2017) .
Non-pharmacological management
Patients with compensated haemolysis or mild anaemia in whom circulatory symptoms are tolerable or absent do not require pharmacological therapy. However, the attitude towards active treatment has probably been too restrictive due to the lack of effective drugs until the last 1-2 decades and an underestimation of the clinical symptoms. In two descriptive studies, 70-80% of the patients were reported to have received drug therapy (Berentsen et al, 2006; Swiecicki et al, 2013) .
There is no reason to change existing recommendations on warm clothing and avoidance of low ambient temperatures, even though these are based on theoretical considerations, clinical experience and review articles (Dacie, 1992b; Berentsen et al, 2007; Hill et al, 2017b; Nydegger et al, 1991) . Many patients have discovered these measures by themselves before they see the specialist. Often, however, it is important for the haematologist to provide doctors and nurses with adequate instructions. In the ward or outpatient department, patients with CAD should keep warm and avoid infusion of cold liquids. Any bacterial infection should be treated (Ulvestad et al, 1999 (Ulvestad et al, , 2001 Berentsen et al, 2007) .
Transfusions can safely be given when indicated, provided the necessary precautions are observed; and the compatibility problems typical for warm-AIHA are not encountered in CAD (Berentsen & Tjonnfjord, 2012) . The patient and the extremity chosen for transfusion should be kept warm, and the use of an in-line blood warmer is recommended (Nydegger et al, 1991; Hill et al, 2017b) . Failure to observe such precautions has resulted in dismal or, very rarely, even fatal outcome (Lodi et al, 2010) . Given that low C4 (and, possibly, C3) levels are rate-limiting for haemolysis, transfusion of blood products with a high plasma content probably carries a risk of exacerbation (Ulvestad et al, 2001) . The detailed consequences of this concern with regard to specific blood products remain unknown.
Plasmapheresis is an option for "first-aid" in critical situations when it is not feasible to wait for the effect of chemoimmunotherapy (Zoppi et al, 1993; von Baeyer, 2003; Szczepiorkowski et al, 2010; Schwartz et al, 2016) . As virtually all IgM is located intravascularly, this procedure is considered highly efficient (Schwartz et al, 2016) , although some conflicting data do exist and no prospective studies have been published (Rosenfield & Jagathambal, 1976; von Baeyer, 2003) . Exchange of 1-1Á5 times the plasma volume with albumin daily or every second day has been recommended (Szczepiorkowski et al, 2010) . The effect is short-lived and pharmacological therapy should be initiated concomitantly.
Three splenectomized patients were reported in one retrospective series, none of whom had responded to the splenectomy (Berentsen et al, 2006) . This is not surprising, since the extravascular haemolysis in CAD predominantly takes place in the liver (Jaffe et al, 1976) . Although exceptions may exist among the rare patients with CA of the IgG class or with a TA approaching 37°C (Silberstein et al, 1987; Dacie, 1992b) , splenectomy should not be used to treat CAD.
CA in patients requiring surgery performed in hypothermia and/or cardiopulmonary bypass is a challenge for thoracic surgeons and anesthesiologists. Routine screening for CA in all individuals scheduled for such surgery is a matter of discussion. Such screening is probably not cost-effective, because the frequency of positive findings is low and the practical consequences of incidentally detected CA not resulting in clinical disease are unclear (Barbara et al, 2013; Jain et al, 2013) . Patients with manifest CAD, however, should have a TA assessment and haematology consultation before cardiac surgery and should be operated under normothermia (Barbara et al, 2013; Tjonnfjord et al, 2017) . Cardiothoracic units should have a policy for management of unexpected agglutination detected during cold cardioplegia (Hill et al, 2017b) .
Unspecific and supportive drug therapies
All estimates of corticosteroid responsiveness have been derived from retrospective data. Although some authors have reported significant response rates (Swiecicki et al, 2013; Barcellini et al, 2014) , most published series have found confirmed responses to be infrequent, probably occurring in less than 20% of patients (Schubothe, 1966; Nydegger et al, 1991; Dacie, 1992b; Berentsen et al, 2006) . Unacceptably high doses are often required to maintain the remission in the few responders (Schreiber et al, 1977; Dacie, 1992b; Berentsen et al, 2006; Stone, 2011) . Therefore, corticosteroids should not be used to treat CAD.
Published series do not support the use of azathioprine, interferon-a or monotherapy with alkylating agents (Worlledge et al, 1968; Hippe et al, 1970; Hillen & Bakker, 1994; Berentsen et al, 2006) , although some conflicting data do exist for interferon-a (O' Connor et al, 1989; Fest et al, 1994; Rordorf et al, 1994) . In my experience, supportive therapy with erythropoietin or its analogues seems quite widely used in North America but not so often in Europe. No studies have been published to support or discourage its use. Although hard clinical evidence seems lacking, folic acid supplementation has often been recommended based on theoretical considerations and expert opinion (Gehrs & Friedberg, 2002; Hill et al, 2017b) .
Therapies directed at the pathogenic B cell clone
Rituximab monotherapy
Rituximab monotherapy is the oldest and most widely used documented drug treatment for CAD (Lee & Kueck, 1998; Berentsen et al, 2004; Sch€ ollkopf et al, 2006; Barcellini et al, 2014) . The highest response rates estimated in the literature, however, probably reflect selection bias in retrospective series, publication bias in case report compilations and meta-analyses, and non-defined or heterogeneous response criteria in both (Berentsen, 2011) . Rates and grading of responses, therefore, should be based on prospective trials. We performed a prospective, uncontrolled trial 37 courses of therapy, using a dosage of 375 mg/m 2 weekly for 4 weeks and strict response criteria (Table II) (Berentsen et al, 2004) . Similar response definitions were used in a Danish study prospectively investigating 20 patients (Sch€ ollkopf et al, 2006) . The overall response rate was 54% and 45%, respectively, in the two studies. With the exception of one complete response (CR) observed in our trial, all remissions were partial responses (PR). In the Norwegian study, responders achieved a median increase in Hb levels of 40 g/l, with a median time to response of 1Á5 months (range, 0Á5-4 months) and a median response duration of 11 months (range, 2-42 months). Six of 10 patients who had been previously treated with rituximab monotherapy, responded to a second course. Adverse events were few and tolerable in both trials as well as a larger, retrospective series (Berentsen et al, 2004 (Berentsen et al, , 2006 Sch€ ollkopf et al, 2006) . Rare cases of hepatitis B reactivation and progressive multifocal leucoencephalopathy have been reported in patients treated with rituximab for polyclonal autoimmune disorders (Cooper & Arnold, 2010) . Causal associations are unclear, however, because of concomitant immunosuppressive therapies and immune dysregulation as part of the autoimmune disease. Administration of four "fixed low doses" (100 mg) rituximab at 1 week intervals has yielded favourable response rates in AIHA in general, but the results are less convincing in CAD than in warm-antibody AIHA (Barcellini et al, 2012) . There are no published systematic data on rituximab maintenance in CAD. Used in the rituximab monotherapy, rituximab-fludarabine and rituximab-bendamustine trials (Berentsen et al, 2004 (Berentsen et al, , 2010 . These criteria are not relevant for trials investigating complement inhibitors.
Rituximab plus fludarabine
State of the art review ª 2018 John Wiley & Sons Ltd were observed in 22 patients (76%); six (21%) achieved CR and 16 (55%) achieved PR. Among 10 patients who had previously been non-responsive to rituximab monotherapy, we observed CR in one patient and PR in six. Median increase in Hb level was 31 g/l in the responders and 40 g/l among those who achieved CR. Median time to response was 4Á0 months, and estimated median response duration was more than 66 months. Although comparison of non-randomized trials must be interpreted with caution, the much higher response rates, promising frequency of CR and long response duration observed after this combination therapy compare favourably with the results achieved by rituximab monotherapy. Toxicity, however, was more frequent with this combination. Haematological toxicity grade 3-4 was observed in 12 patients (41%), including grade 4 neutropenia in four (14%) (Berentsen et al, 2010) . Seventeen patients (59%) experienced grade 1-3 infection. All infections were successfully treated except for one old, frail non-responder who died of pneumonia after 9 months. Three patients (10%) suffered herpes zoster reactivation, but Pneumocystis jirovecii pneumonia or infection grade 4 was not observed. Fludarabine-induced warm-antibody AIHA did not occur, but three patients (10%) experienced a transient, mild exacerbation of CAD precipitated by infection (Ulvestad et al, 2001; Berentsen et al, 2010) . The study was not designed to address the risk of late-occurring haematological malignancies, which have been reported after fludarabine-based therapy for Waldenstr€ om macroglobulinaemia (Treon et al, 2009 ).
Rituximab plus bendamustine
In a recently published, prospective non-randomized Nordic multicentre trial, we treated 45 eligible patients with rituximab 375 mg/m 2 day 1 and bendamustine 90 mg/m 2 days 1 and 2 for 4 cycles of 28 days each . The inclusion criteria and response definitions were identical to those used in the rituximab-fludarabine trial (Table II) . The baseline characteristics were also very similar, with a median age of 74 years (range, 48-86 years) in the rituximab-bendamustine study. Thirty-two patients (71%) responded to the rituximab plus bendamustine combination: 18 (40%) achieved CR and 14 (31%) PR. Among 14 patients previously treated with rituximab or fludarabine-rituximab, 7 (50%) responded to bendamustine-rituximab, with three patients achieving CR and four PR. Hb levels increased by median 44 g/l in the complete responders; 39 g/l in those achieving PR and 37 g/l in the whole cohort. The 10-percentile of response duration was not reached after 32 months. Grade 4 neutropenia occurred in 9 patients (20%), but only 5 (11%) experienced infection with or without neutropenia. Most clinical adverse events were mild and could be attributed to the known non-haematological toxicity of bendamustine. Thirteen patients (29%) had their dose of bendamustine reduced.
Even when taking into account the usual reservations in comparing independent trials, it seems beyond any doubt that the CR rate was nearly doubled in the rituximab-bendamustine study as compared with fludarabine-rituximab. The overall response rates were similar. The observed response duration was equally long or longer with bendamustine plus rituximab. There seems to be a lower frequency of severe neutropenia following therapy with bendamustine-rituximab, but the significance of this modest difference between independent trials is uncertain. However, the difference in the infection rate was striking (11% following the bendamustinerituximab combination compared with 59% after fludarabine-rituximab). In conclusion, we consider bendamustine plus rituximab at least as efficient as fludarabine plus rituximab and substantially less toxic.
Other B cell-directed therapies Two case reports have described favourable response to bortezomib alone or in combination (Carson et al, 2010; Danchaivijitr et al, 2011) . In a recently completed Italian prospective trial, 19 evaluable patients received a single course of bortezomib monotherapy, 1Á3 mg/m 2 intravenously on days 1, 4, 8 and 11 (Rossi et al, 2017) . Three patients achieved a CR, defined as normal haemoglobin levels with no signs of haemolysis, and three achieved PR. Although these response rates seem modest, they indicate that bortezomib may be tried in patients who have not responded to rituximab monotherapy and in whom rituximab-bendamustine combination therapy has failed or is contra-indicated. The data should also warrant further trials of bortezomib in an extended dosage schedule and/or as part of combination therapy.
Complement-directed therapies
Case reports have described a beneficial effect of the monoclonal anti-C5 antibody eculizumab in treatment of severe CAD as well as in preventing exacerbation triggered by cardiac surgery (R€ oth et al, 2009; Tjonnfjord et al, 2017) . The results of a prospective study of eculizumab therapy in 13 patients with CAD has also been presented (R€ oth et al, 2015) . Although the rise in Hb levels was marginal, at 9Á0 g/ l, there was a significant reduction in lactate dehydrogenase levels and improvement in quality of life; and most patients achieved transfusion independency. Taking into consideration that eculizumab does not target the part of the complement system shown to be most important in CAD, better results might be expected with inhibitors of the classical pathway (Fig 2) . An immediate cessation of haemolysis was observed following pharmacological doses of plasma-derived C1-esterase inhibitor concentrate in a patient with a severe, IgM-driven, complement-mediated warm-antibody AIHA that was refractory to other therapies (Wouters et al, 2013) . In vitro experiments have shown that ANX005, a humanized monoclonal antibody that inhibits C1q, prevents C4 and C3 fragment deposition on human erythrocytes exposed to CAD sera, resulting in a dose-dependent reduction in haemolysis (Gertz et al, 2016) .
The effect of the anti-C1s mouse monoclonal antibody TNT003 has been studied in vitro (Shi et al, 2014) , and its humanized counterpart BIVV009 (formerly known as TNT009) has recently been investigated in a phase 1B clinical trial . The in vitro experiments tested the effects of TNT003 on CA-induced complement activity against human erythrocytes. Using CA samples from 40 patients with CAD, the authors found that the monoclonal antibody efficiently inhibited CA-induced deposition of C3 fragments on the erythrocytes and prevented erythrophagocytosis by a phagocytic cell line (Shi et al, 2014) . TNT003 also inhibited the CA-induced, classical pathway-driven generation of anaphylotoxins C4a, C3a and C5a. Interestingly, CA from only one patient sample out of 40 was able to directly induce MAC-mediated haemolysis.
In the clinical trial, six patients with typical primary CAD received a test dose of 10 mg/kg BIVV009 followed by a full dose of 60 mg/kg 1-4 days later . Three additional doses of 60 mg/kg were then administered at 1-week intervals, and a weekly fixed dose of 5Á5 g was used for maintenance. All patients received vaccination against meningococci and pneumococci. BIVV009 was well tolerated and immediately stopped haemolysis in all of these six severely anaemic patients, increasing Hb levels by a mean of 43 g/l and eliminating transfusion requirements while on therapy. Infectious or autoimmune complications did not occur. The favourable safety profile has to be confirmed by further clinical trials.
Complement modulation cannot be expected to improve clinical manifestations caused by the erythrocyte agglutination itself, i.e. acrocyanosis and Raynaud phenomena. Furthermore, in contrast to most therapies targeting the pathogenic B cell clone, complement-directed therapies will have to be continued infinitely in order to maintain their effect. Still, there is an obvious need for complement inhibition in some situations. First, at least 25% of the patients do not benefit from chemoimmunotherapy because of contraindications or failure. Second, the very short time to response to C1s-directed therapy will allow a rapidly acting treatment to be instituted in critically anaemic patients and acute situations, offering a bridge to the slower effect of chemoimmunotherapy when relevant.
The future
Can therapy for CAD be evidence-based?
Most treatment options in AIHA have been based on expert opinion, case reports, theoretical considerations and clinical experience rather than prospective clinical trials. Case reports and small retrospective series are highly likely to suffer from publication bias and heterogeneous or poorly defined response criteria. We have previously analysed papers describing rituximab monotherapy for CAD as a typical example: Both pooled case reports and prospective studies have been published and the results are totally different (Berentsen, 2011) .
Even though CAD is an infrequent disease, reliable prospective uncontrolled studies are possible to perform and several examples have been referenced in this review. In my experience, controlled randomized studies are difficult to undertake in CAD, even at a multicentre level, because of limitations in number of patients and statistical power. Perspectives learnt from the recent BIVV009 studies, however, may indicate that even controlled randomized trials should be feasible if very broad, international cooperation can be involved . Therapy, as far as possible, should be based on prospective studies, including good nonrandomized trials. Response rates derived from pooled case reports should not be accepted as a basis for recommendations.
Future therapy perspectives
The potential of proteasome inhibitors as part of combinations and/or in an extended dosage schedule remains to be investigated (Rossi et al, 2017) .
Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, specifically target both the B-cell receptor (BCR) and toll-like receptor(TLR)4-MYD88 signal pathways (Treon et al, 2015; Desai et al, 2015) . Given that the MYD88 L265P mutation has been shown to result in the over-activation of BTK, the theoretical rationale for ibrutinib is somewhat weaker in CAD than in Waldenstr€ om macroglobulinaemia. Until a prospective trial has been performed, therefore, it is unclear whether a BTK inhibitor would be useful in the treatment of CAD. Among other BCR pathway-modulating drugs, idelalisib and venetoclax have been approved for some B cell LPDs (Roberts et al, 2016) . None of these targeted therapies has been systematically investigated in CAD, and prospective trials would be highly valuable.
Complement inhibition in CAD should be further documented and developed and, in particular, extended clinical studies of BIVV009 are warranted (Shi et al, 2014; Jaeger, 2017) . Other novel complement inhibitors are also being developed (Risitano, 2015; Gertz et al, 2016) . Compstatin is a group of low molecular weight peptides that block cleavage of C3 (Mastellos et al, 2015) . Although no data have been published for CA-induced haemolysis, compstatin has been found to efficiently prevent in vitro lysis of red blood cells from patients with paroxysmal nocturnal haemoglobinuria (Risitano et al, 2014) . In theory, C3 inhibition, which will probably result in blocking the whole complement system, might be more dangerous regarding risk of infection than the still more proximal, selective inhibition of C1s, which State of the art review ª 2018 John Wiley & Sons Ltd will leave the alternative and lectin complement pathways intact (Berentsen, 2014) . Clinical studies will have to address this safety issue.
Conclusions
CAD should be distinguished from secondary CAS. Nonpharmacological management is still appropriate for patients with compensated haemolysis or symptomless haemolytic anaemia and mild or no circulatory symptoms. Pharmacological therapy has improved considerably during the last 10-15 years and is based upon an understanding of CAD as a low-grade clonal lymphoproliferative disorder resulting in complement-dependent haemolysis.
Patients requiring drug therapy should be considered for prospective trials whenever such studies are available. Outside clinical trials, rituximab plus bendamustine may be used in the first line for reasonably fit patients. In frail, multimorbid patients, those in whom bendamustine is contraindicated and those reluctant to receive cytotoxic drugs, the first-line treatment is rituximab monotherapy. In the second-line situation, a bortezomib-based regimen may be an option. An alternative will be rituximab-fludarabine in fit patients who are not too young. Complement classical pathway-inhibitors will probably be available outside clinical trials in the relatively near future. Such therapy can be expected to become a good alternative in the second line and, probably, as first choice in patients who require rapidly acting therapy.
